Ruchi Taliwal, MD
Family Medicine · Fairlawn, OHNPI 1386634681
Payments from drug & device makers
Across 159 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$425
- AbbVie$397
- Novo Nordisk$217
- GSK$185
- Astellas Pharma US Inc$182
- AstraZeneca$150
- plus $857 from 19 others
What the payments were for
- Food & beverage$2,39799%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $425 |
| AbbVie(2 entities) | 23 | $397 |
| Novo Nordisk | 16 | $217 |
| GSK | 16 | $185 |
| Astellas Pharma US Inc | 10 | $182 |
| AstraZeneca | 10 | $150 |
| Novartis | 9 | $135 |
| Amarin Pharma, Inc. | 8 | $125 |
| Lilly USA, LLC | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Amgen | 4 | $57 |
| Merck | 3 | $39 |
| Radius Health, Inc. | 3 | $38 |
| Bausch Health US, LLC | 3 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $24 |
| IBSA Pharma Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,414 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $86,497 |
| FarxigaDapagliflozin Propanediol | 71 | $84,074 |
| MounjaroTirzepatide | 41 | $62,706 |
| EliquisApixaban | 42 | $55,871 |
| TrulicityDulaglutide | 41 | $54,266 |
| Xigduo XrDapaglifloz Propaned/Metformin | 38 | $42,399 |
| ProliaDenosumab | 19 | $33,198 |
| JardianceEmpagliflozin | 14 | $16,748 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $15,351 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,040 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $14,753 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $9,661 |
| Celecoxib | 49 | $3,287 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 98 | $2,781 |
| Atorvastatin Calcium | 292 | $2,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $72 | $116,97282 claims |
| Novo NordiskOzempic | $217 | $86,49754 claims |
| AstraZenecaFarxiga | $150 | $84,07471 claims |
| PfizerEliquis | $425 | $55,87142 claims |
| AmgenProlia | $57 | $33,19819 claims |
| Boehringer IngelheimJardiance | $24 | $16,74814 claims |
| GSKTrelegy Ellipta | $185 | $15,04014 claims |
| MerckJanumet Xr | $39 | $9,66113 claims |
| AbbVieSynthroid | $397 | $1,68149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fairlawn
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.